VivoSeq
Immunology

Chronic Graft Versus Host Disease

51

Pipeline Programs↗

28

Active Trials↗

29

Companies Involved↗

Chronic Graft Versus Host Disease is a moderately active landscape with 51 programs across 29 companies. The most active players are Sanofi, Azurity Pharmaceuticals, Bristol-Myers Squibb. 9 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

25/100

Mech. Concentration

18/100

Completion Rate

72/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 1A

Azurity Pharmaceuticals

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1E

Essen Biotech

1 program

Phase 1B

Bellicum Pharmaceuticals

1 program

Phase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

74%

Small molecule

39 of 53 classified programs — the dominant modality here.

26%ALL OTHERSProtein / enzyme713%Monoclonal antibody48%Cell therapy36%

Small molecule leads; the ring shows all 53 classified programs, each share of the total. Modality classified for 98% of 56 pipeline programs.

Analysis

Trial Status

111

clinical trials

Completed51 · 46%
Recruiting16 · 14%
Terminated15 · 14%
Unknown status12 · 11%
Active, not recruiting11 · 10%
Withdrawn4 · 4%
Other2 · 2%

Clinical Trials

Trial Activity

111 trials

A Pilot Study to Correlate 4-18F- Fluoro-1-naphthol 18F-4FN PET/CT Imaging With Chronic Graft Versus Host Disease Manifestations
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07325253·16 enrolled
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
Recruiting·Sanofi logoSanofi·Phase 2·NCT07116031·37 enrolled
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
Recruiting·NNorthside Hospital, Inc.·Phase 2·NCT06046248·25 enrolled
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
Recruiting·Incyte logoIncyte·Phase 2·NCT06388564·120 enrolled
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
Recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT06682169·182 enrolled
Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Severity
Recruiting·—·Phase 2·NCT06756061·88 enrolled
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
Recruiting·Incyte logoIncyte·Phase 2·NCT07124078·60 enrolled
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT03779854·68 enrolled
A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease
Recruiting·QQurient Co., Ltd.·Phase 1·NCT07138196·18 enrolled
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Recruiting·MMayo Clinic·Phase 2·NCT06271616·40 enrolled
A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease
Recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT06300320·52 enrolled
Axatilimab for Sclerotic Chronic Graft-versus-Host Disease
Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT07011810·50 enrolled
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT05996627·82 enrolled
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357)
Recruiting·Incyte logoIncyte·Phase 3·NCT06585774·240 enrolled
A Phase II b Study of Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
Recruiting·UUniversity of Miami·Phase 2·NCT06663722·49 enrolled
Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)